Biaxin, the brand name for clarithromycin, is a macrolide antibiotic that treats susceptible bacterial infections by inhibiting bacterial protein synthesis. Clinicians commonly prescribe it for community-acquired pneumonia, acute bacterial sinusitis, streptococcal pharyngitis (strep throat), acute bacterial exacerbations of chronic bronchitis, and uncomplicated skin and soft tissue infections caused by susceptible organisms. In pediatrics, the oral suspension is frequently used for otitis media and pharyngitis where clarithromycin is deemed appropriate.
Biaxin also has an important role in gastrointestinal care: as part of combination therapy for Helicobacter pylori–associated peptic ulcer disease. In this setting, clarithromycin is used with a proton pump inhibitor and additional antibiotics to eradicate H. pylori and reduce ulcer recurrence. In select immunocompromised patients, particularly those with advanced HIV, clarithromycin may be used for prophylaxis or treatment of Mycobacterium avium complex (MAC) in accordance with current guidelines.
Because antibiotic resistance patterns vary by region and patient factors, culture results, local antibiograms, and guideline recommendations guide whether Biaxin is the right antibiotic. Viral infections (like the common cold or flu) do not respond to clarithromycin; using antibiotics when they are not needed increases the risk of side effects and antimicrobial resistance.
Dosing of Biaxin depends on the indication, formulation, age, renal function, hepatic status, and concomitant medications. Always follow a clinician’s prescription and product labeling.
Adults (immediate-release tablets): Most respiratory tract and skin infections are treated with 250–500 mg every 12 hours for 7–14 days, depending on severity and organism susceptibility. For community-acquired pneumonia or more severe infections, 500 mg twice daily is common.
Adults (extended-release tablets): 1,000 mg once daily for 7–14 days may be used for certain respiratory infections. Extended-release tablets must be taken with food and swallowed whole—do not crush or split.
H. pylori eradication (adults): Clarithromycin 500 mg twice daily combined with a proton pump inhibitor plus a second antibiotic (often amoxicillin 1 g twice daily or metronidazole) for 10–14 days is a typical regimen. Due to rising resistance, clinicians increasingly choose alternative quadruple therapies; your provider will tailor treatment to local resistance patterns and your allergy profile.
Mycobacterium avium complex: 500 mg twice daily is commonly used, often with additional antimycobacterial agents. Duration and combinations follow HIV and infectious disease guidelines.
Pediatrics: Weight-based dosing is used for immediate-release suspension (typically 7.5 mg/kg every 12 hours up to a maximum, depending on indication). Use calibrated measuring devices for accuracy; household spoons are unreliable.
Renal impairment: For creatinine clearance less than 30 mL/min, dose reduction (usually halving the dose and/or extending the dosing interval) is recommended. In severe renal and hepatic impairment, alternatives may be preferred.
Administration tips: Immediate-release tablets and suspension may be taken with or without food; taking with food can reduce gastrointestinal upset. Do not miss doses; maintain consistent intervals to optimize bacterial eradication.
Allergy and prior reactions: Avoid Biaxin if you have a known hypersensitivity to clarithromycin, erythromycin, azithromycin, or other macrolides/ketolides. Report any history of severe rash, anaphylaxis, or cholestatic hepatitis associated with macrolides.
Heart rhythm risks: Clarithromycin can prolong the QT interval and rarely cause torsades de pointes, especially in patients with existing QT prolongation, arrhythmias, uncorrected hypokalemia or hypomagnesemia, or those taking other QT-prolonging drugs (for example, sotalol, amiodarone, certain antipsychotics). Baseline risk assessment and medication review are essential.
Liver and kidney function: Hepatotoxicity (including cholestatic hepatitis) has been reported. Use caution in patients with hepatic impairment, and reduce dose in significant renal impairment. Seek care if you develop jaundice, dark urine, severe fatigue, or right upper quadrant pain.
Myasthenia gravis: Macrolides may exacerbate symptoms. Clarithromycin can unmask or worsen weakness; consult your neurologist and prescriber.
Microbiome and C. difficile: Like other antibiotics, Biaxin can disrupt gut flora and precipitate Clostridioides difficile–associated diarrhea. Report severe or persistent diarrhea, especially with blood or fever, during or after therapy.
Pregnancy and lactation: Clarithromycin should be used in pregnancy only if the potential benefit justifies the potential risk. It is excreted in breast milk; weigh benefits and risks with your clinician. Alternative antibiotics may be preferred for certain conditions.
Antibiotic stewardship: Use clarithromycin only when indicated and complete the full course as prescribed to reduce resistance and treatment failure.
Do not take Biaxin if you have:
• Known hypersensitivity to clarithromycin, erythromycin, other macrolides, or ketolides.
• A history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
• Concomitant use of medications that carry serious interaction risks via CYP3A inhibition, including: cisapride, pimozide, ergotamine or dihydroergotamine, and certain HMG-CoA reductase inhibitors (simvastatin or lovastatin), due to risks of arrhythmia or severe myopathy/rhabdomyolysis.
• Concomitant colchicine in patients with renal or hepatic impairment (risk of fatal toxicity). Even without impairment, extreme caution and monitoring are required if coadministered.
Common adverse effects include nausea, vomiting, abdominal pain, diarrhea, dyspepsia, headache, and an altered or metallic taste (dysgeusia). Mild transient elevations in liver enzymes can occur. Some people report insomnia or vivid dreams; most effects resolve after the course ends.
Less common but notable reactions include rash, pruritus, photosensitivity, and reversible hearing changes (especially at higher doses or in renal impairment). Hypoglycemia can occur when used with certain antidiabetic medications.
Serious reactions are rare but require immediate attention: severe allergic reactions (anaphylaxis, angioedema), Stevens–Johnson syndrome/toxic epidermal necrolysis, cholestatic hepatitis, pancreatitis, severe colitis (including C. difficile), QT prolongation and torsades de pointes, severe myopathy or rhabdomyolysis (especially with interacting statins), and neuropsychiatric symptoms (confusion, hallucinations) in susceptible individuals. Seek urgent care if you experience chest palpitations, syncope, persistent jaundice, severe abdominal pain, or skin/mucosal blistering.
Clarithromycin is a strong inhibitor of CYP3A4 and P-glycoprotein and can raise blood levels of many drugs. A thorough medication review—including over-the-counter drugs and supplements—is essential before starting Biaxin.
Anticoagulants and antiplatelets: Warfarin’s effect can be potentiated, raising INR and bleeding risk; close INR monitoring and dose adjustments are often needed. Direct oral anticoagulants (e.g., apixaban, rivaroxaban) may have increased exposure; prescribers may choose alternatives or adjust therapy.
Antiarrhythmics and QT-prolonging agents: Combining with amiodarone, sotalol, dofetilide, certain antipsychotics, or fluoroquinolones can increase QT prolongation risk. Avoid prohibited combinations and correct electrolytes.
Statins: Simvastatin and lovastatin are contraindicated with clarithromycin due to high myopathy/rhabdomyolysis risk. For patients requiring lipid therapy, clinicians may temporarily hold statins or switch to a non–CYP3A statin (e.g., pravastatin) with caution.
Cardiovascular drugs: Clarithromycin can increase calcium channel blocker levels (verapamil, diltiazem), sometimes causing hypotension or bradycardia. Digoxin exposure can rise, necessitating monitoring for toxicity (nausea, visual changes, arrhythmias).
CNS depressants: Enhanced sedation and respiratory depression may occur with certain benzodiazepines (midazolam, triazolam) and related agents; dose adjustments or alternatives are considered.
Antidiabetics: Risk of hypoglycemia may increase with sulfonylureas and insulin; monitor glucose closely.
Antiepileptics and others: Levels of carbamazepine and theophylline may increase; rifampin, rifabutin, efavirenz, and phenytoin can reduce clarithromycin exposure (enzyme induction), potentially decreasing efficacy. HIV protease inhibitors (e.g., ritonavir) can increase clarithromycin levels; dose adjustments or alternative antibiotics may be needed.
Colchicine and ergot alkaloids: Concomitant use raises the risk of life-threatening toxicity; avoid as noted in contraindications.
Herbals and supplements: St. John’s wort induces CYP3A and may reduce clarithromycin levels; avoid concurrent use. Always disclose supplements to your clinician.
If you miss a dose of Biaxin, take it as soon as you remember unless it is close to the time for your next dose. Do not double up to catch up. Resume your regular schedule and complete the full prescribed course to help prevent resistance and relapse.
Symptoms of overdose may include significant gastrointestinal distress (nausea, vomiting, abdominal pain), headache, dizziness, and, rarely, cardiac rhythm disturbances due to QT prolongation. If an overdose is suspected, seek emergency medical care or contact a poison control center immediately. Management is supportive: consider early gastric decontamination for large recent ingestions, monitor electrolytes, liver enzymes, and ECG, and treat arrhythmias per advanced cardiac life support protocols. Hemodialysis and peritoneal dialysis are unlikely to enhance clarithromycin clearance.
Store Biaxin immediate-release and extended-release tablets at controlled room temperature (typically 20–25°C/68–77°F) in a dry place, away from excess heat and humidity. Keep in the original container with the child-resistant cap securely closed.
For the oral suspension, follow the pharmacist’s mixing instructions. Once reconstituted, store at room temperature—do not refrigerate—and discard any unused portion after 14 days. Shake well before each dose to ensure uniform dispersion. Keep all medications out of reach of children and pets.
In the United States, Biaxin (clarithromycin) is a prescription-only antibiotic. It should not be purchased or used without a valid prescription from a licensed clinician, both for legal reasons and to ensure appropriate diagnosis, dosing, and safety monitoring. Using antibiotics without medical guidance can lead to treatment failure, serious drug interactions, and antibiotic resistance.
Culpeper Regional Health System offers a legal, structured pathway to care: schedule an in-person or telehealth visit with a qualified clinician who will evaluate your symptoms, review your medical history and medications, and determine whether Biaxin is appropriate. If indicated, the clinician will issue a legitimate prescription and coordinate with a trusted pharmacy for fulfillment. This clinician-guided approach protects your health, reduces the risk of adverse drug interactions (for example, with warfarin, statins, or antiarrhythmics), and ensures you receive the right antibiotic for the right infection and duration. For streamlined access, contact Culpeper Regional Health System to arrange an evaluation and discuss evidence-based treatment options tailored to you.
Biaxin is a macrolide antibiotic. It stops susceptible bacteria from growing by binding to the 50S ribosomal subunit and inhibiting protein synthesis.
Clarithromycin is used for sinus infections, acute exacerbations of chronic bronchitis, community-acquired pneumonia, skin and soft tissue infections, strep throat in penicillin-allergic patients, Helicobacter pylori eradication (as part of combination therapy), and prevention or treatment of Mycobacterium avium complex when used in combination. It does not treat viral infections like colds or flu.
Immediate-release tablets and oral suspension may be taken with or without food. Extended-release tablets (Biaxin XL) must be taken once daily with food and swallowed whole; do not crush or split them.
Typical adult doses are 250–500 mg every 12 hours for 7–14 days, depending on the infection. For H. pylori, 500 mg every 12 hours for 14 days with a proton pump inhibitor and another antibiotic. Biaxin XL is commonly 1,000 mg once daily with food. Follow your clinician’s specific prescription. Reduce the dose in severe kidney impairment.
Most people begin to feel improvement within 48–72 hours. Finish the full prescribed course even if you feel better early to prevent relapse and antibiotic resistance.
A metallic or bitter taste, nausea, diarrhea, stomach pain, headache, and trouble sleeping are common. These are usually mild and resolve after treatment ends.
Contact a clinician urgently for severe or persistent diarrhea (possible C. difficile), yellowing of skin/eyes or dark urine (liver injury), fainting or heart palpitations (QT prolongation/arrhythmia), severe rash or swelling (allergic reaction), or unusual muscle pain or weakness, especially if you are on a statin.
People with a history of QT prolongation or torsades de pointes, significant liver disease, severe kidney disease without dose adjustment, or myasthenia gravis should use caution or avoid clarithromycin. It may increase long-term cardiac risk in people with coronary artery disease; discuss alternatives with your clinician.
Clarithromycin strongly inhibits CYP3A4 and P-glycoprotein. Serious interactions include simvastatin, lovastatin, colchicine, ergot alkaloids, pimozide, cisapride, lomitapide, and some antiarrhythmics. It can raise levels of warfarin (increasing INR), digoxin, carbamazepine, certain benzodiazepines, some opioids, and calcium channel blockers. Always review your full medication list with a healthcare professional.
Do not combine clarithromycin with simvastatin or lovastatin due to high risk of severe muscle injury. If a statin is needed, clinicians may temporarily hold it or switch to an alternative such as pravastatin or a carefully monitored low dose of rosuvastatin. Do not change medications without medical advice.
Alcohol does not directly interact with clarithromycin, but it can worsen stomach upset, dizziness, and dehydration. Limiting or avoiding alcohol is wise during treatment.
Pregnancy data are limited and alternatives like azithromycin are often preferred when appropriate. Clarithromycin passes into breast milk; it is generally compatible with breastfeeding, but monitor the infant for loose stools or thrush. Discuss risks and benefits with your clinician.
Take it as soon as you remember unless it is close to the next dose. Do not double up. For once-daily Biaxin XL, take the missed dose the same day with food if remembered within several hours.
Yes, when bacteria are susceptible and macrolides are appropriate. However, macrolide resistance among Streptococcus pneumoniae and Group A strep is common in some regions, so clinicians may prefer other antibiotics based on local resistance patterns.
Clarithromycin can prolong the QT interval and rarely cause dangerous arrhythmias, especially in people with existing QT prolongation, low potassium or magnesium, or when combined with other QT-prolonging drugs. Report palpitations, dizziness, or fainting promptly.
Any antibiotic can disrupt normal flora. Some people develop vaginal yeast infections or antibiotic-associated diarrhea, including C. difficile. Seek care for severe or bloody diarrhea, fever, or abdominal cramping.
It is not a first-line option for UTIs because common urinary pathogens are often resistant and better-targeted antibiotics are available. Treatment should be guided by symptoms, cultures, and local resistance.
Probiotics may help reduce antibiotic-associated diarrhea for some. If you use one, separate it from your antibiotic dose by a few hours. Probiotics are optional and not a replacement for medical care.
Both are macrolide antibiotics effective against many respiratory and atypical pathogens. Azithromycin has fewer drug interactions and a longer half-life allowing shorter, once-daily regimens, while clarithromycin may have stronger activity against H. pylori and some respiratory bacteria due to its active metabolite. The best choice depends on the infection, interactions, and local resistance.
Neither macrolide is first-line in many guidelines because of resistance; amoxicillin/clavulanate is often preferred. If a macrolide is used, both can work, but clarithromycin’s active metabolite adds activity against Haemophilus influenzae. Azithromycin is favored when avoiding drug interactions or for simpler dosing.
Both can cause GI upset and QT prolongation. Clarithromycin more commonly causes a metallic taste and has more clinically significant drug interactions. Azithromycin is generally better tolerated but can still cause diarrhea and, rarely, heart rhythm issues.
Clarithromycin. It is a strong CYP3A4 and P-gp inhibitor and interacts with many drugs (statins, warfarin, digoxin, benzodiazepines, colchicine). Azithromycin has minimal CYP interactions, so it is often chosen when polypharmacy is a concern.
Azithromycin is typically dosed once daily for 3–5 days (e.g., 500 mg on day 1, then 250 mg daily). Clarithromycin is usually 250–500 mg twice daily for 7–14 days; the XL form is once daily. For adherence, a Z-Pak is often simpler.
Clarithromycin generally causes less gastrointestinal cramping and diarrhea than erythromycin, which strongly stimulates motilin receptors. Clarithromycin also offers twice-daily dosing and improved activity against H. influenzae.
Erythromycin has longer experience in pregnancy. Clarithromycin has limited human data and is often avoided when safer alternatives are suitable. Always individualize therapy based on risks and benefits.
Both deliver clarithromycin but with different dosing. Biaxin XL is taken once daily with food and should not be split or crushed; immediate-release is taken twice daily with or without food. Choice depends on adherence needs, GI tolerance, and clinician preference.
Telithromycin is a ketolide related to macrolides. Due to risks of severe liver injury, visual disturbances, and exacerbation of myasthenia gravis, its use is highly restricted. Clarithromycin is preferred for typical macrolide indications.
Roxithromycin is a macrolide not available in the United States. It has a longer half-life and somewhat fewer GI effects than erythromycin, but direct comparisons vary by region and indication. Where available, selection depends on susceptibility, dosing convenience, and interactions.
Clarithromycin is the standard macrolide in triple or quadruple therapy for H. pylori. Azithromycin is not routinely used for this purpose. Where clarithromycin resistance rates are high, non-clarithromycin regimens may be preferred.
Both are active and used with ethambutol (± a rifamycin). Azithromycin is often favored because of fewer drug interactions and convenient dosing, but clarithromycin remains an effective option when interactions are manageable and susceptibility is confirmed.
Yes. Macrolide resistance mechanisms (erm methylation and mef efflux) often confer cross-resistance across clarithromycin, azithromycin, and erythromycin. If a pathogen is resistant to one macrolide, it is likely resistant to the others.
Lets get in touch if you have any questions.